Response to Chiasson et al.: Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data.
Sawicki
P T
PT
DIeM-Institute for Evidence Based Medicine, Venloer Str. 301-303, 50823, Cologne, Germany, peter.sawicki@t-online.de
Kaiser
T
T
D020909:Acarbose / Q000009:adverse effects / Q000627:therapeutic use*; D001795:Blood Pressure Determination / Q000379:methods; D002318:Cardiovascular Diseases / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control*; D002985:Clinical Protocols; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control*; D004311:Double-Blind Method; D005858:Germany; D018149:Glucose Intolerance / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control*; D015201:Meta-Analysis as Topic; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D015203:Reproducibility of Results; D012107:Research Design; D013997:Time Factors; D016896:Treatment Outcome
D020909:Acarbose